FY2025 EPS Estimates for SLNO Raised by Cantor Fitzgerald

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for Soleno Therapeutics in a report issued on Wednesday, July 16th. Cantor Fitzgerald analyst K. Kluska now expects that the company will earn ($2.10) per share for the year, up from their prior estimate of ($3.44). Cantor Fitzgerald currently has a "Overweight" rating and a $123.00 price target on the stock. The consensus estimate for Soleno Therapeutics' current full-year earnings is ($3.72) per share. Cantor Fitzgerald also issued estimates for Soleno Therapeutics' FY2026 earnings at $0.84 EPS.

SLNO has been the subject of several other reports. Cowen initiated coverage on Soleno Therapeutics in a report on Monday, June 23rd. They set a "buy" rating for the company. Guggenheim increased their price target on Soleno Therapeutics from $81.00 to $97.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Stifel Nicolaus increased their price target on Soleno Therapeutics from $74.00 to $108.00 and gave the stock a "buy" rating in a report on Friday, March 28th. Piper Sandler raised their target price on Soleno Therapeutics from $93.00 to $145.00 and gave the company an "overweight" rating in a report on Thursday, April 24th. Finally, Robert W. Baird set a $121.00 target price on Soleno Therapeutics and gave the company an "outperform" rating in a report on Friday, July 11th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $108.70.

Soleno Therapeutics Stock Performance

Shares of SLNO traded up $0.10 during mid-day trading on Friday, reaching $87.74. 111,939 shares of the company's stock were exchanged, compared to its average volume of 1,057,626. The company has a debt-to-equity ratio of 0.21, a current ratio of 19.64 and a quick ratio of 19.64. The stock has a market capitalization of $4.42 billion, a PE ratio of -18.99 and a beta of -2.63. The business's fifty day simple moving average is $79.60 and its 200-day simple moving average is $63.75. Soleno Therapeutics has a 52-week low of $41.50 and a 52-week high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.14) by $0.19.

Institutional Trading of Soleno Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc grew its holdings in Soleno Therapeutics by 9.2% in the 4th quarter. Legal & General Group Plc now owns 23,471 shares of the company's stock valued at $1,055,000 after buying an additional 1,983 shares during the period. Emerald Advisers LLC raised its position in shares of Soleno Therapeutics by 85.4% in the 4th quarter. Emerald Advisers LLC now owns 580,919 shares of the company's stock valued at $26,112,000 after purchasing an additional 267,585 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Soleno Therapeutics by 13.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 217,550 shares of the company's stock valued at $9,779,000 after purchasing an additional 24,953 shares in the last quarter. Sei Investments Co. raised its position in shares of Soleno Therapeutics by 47.0% in the 4th quarter. Sei Investments Co. now owns 16,444 shares of the company's stock valued at $739,000 after purchasing an additional 5,258 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in shares of Soleno Therapeutics by 4,377.3% in the 1st quarter. GAMMA Investing LLC now owns 3,358 shares of the company's stock valued at $240,000 after purchasing an additional 3,283 shares in the last quarter. Hedge funds and other institutional investors own 97.42% of the company's stock.

Insider Buying and Selling at Soleno Therapeutics

In other news, insider Patricia C. Hirano sold 3,830 shares of the firm's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $82.76, for a total value of $316,970.80. Following the completion of the transaction, the insider owned 13,206 shares in the company, valued at $1,092,928.56. This trade represents a 22.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 6.40% of the stock is currently owned by corporate insiders.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.